TABLE 2.
TRPS1 and Tumor Phenotype
| TRPS1 immunostaining result | ||||||
|---|---|---|---|---|---|---|
| n | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | P | |
| Invasive breast carcinoma of no special type | ||||||
| pT1 | 697 | 6.5 | 5.3 | 30.0 | 58.2 | <0.0001 |
| pT2 | 600 | 13.2 | 8.7 | 29.0 | 49.2 | — |
| pT3-4 | 120 | 18.3 | 6.7 | 31.7 | 43.3 | — |
| G1 | 166 | 4.8 | 6.0 | 36.1 | 53.0 | 0.0547 |
| G2 | 758 | 10.3 | 7.0 | 27.8 | 54.9 | — |
| G3 | 533 | 12.0 | 7.1 | 30.8 | 50.1 | — |
| pN0 | 635 | 9.0 | 7.1 | 30.7 | 53.2 | 0.0571 |
| pN1 | 316 | 11.4 | 6.3 | 31.6 | 50.6 | — |
| pN2 | 112 | 14.3 | 11.6 | 30.4 | 43.8 | — |
| pN3 | 68 | 20.6 | 11.8 | 22.1 | 45.6 | — |
| pM0 | 177 | 5.1 | 6.2 | 37.3 | 51.4 | 0.0072 |
| pM1 | 111 | 15.3 | 9.9 | 37.8 | 36.9 | — |
| HER2 negative | 832 | 7.8 | 6.7 | 29.1 | 56.4 | 0.5888 |
| HER2-positive | 114 | 7.9 | 7.0 | 35.1 | 50.0 | — |
| ER-negative | 197 | 18.3 | 8.6 | 39.1 | 34.0 | <0.0001 |
| ER-positive | 706 | 4.7 | 6.2 | 27.2 | 61.9 | — |
| PR-negative | 374 | 14.2 | 9.1 | 34.5 | 42.2 | <0.0001 |
| PR-positive | 564 | 3.4 | 5.0 | 26.8 | 64.9 | — |
| Non-triple negative | 742 | 5.0 | 6.5 | 28.8 | 59.7 | <0.0001 |
| Triple negative | 133 | 22.6 | 9.0 | 33.1 | 35.3 | — |
| Endometrioid endometrial carcinoma | ||||||
| pT1 | 79 | 83.5 | 11.4 | 2.5 | 2.5 | 0.9265 |
| pT2 | 22 | 81.8 | 9.1 | 4.5 | 4.5 | — |
| pT3-pT4 | 23 | 82.6 | 13.0 | 4.3 | 0.0 | — |
| pN0 | 37 | 75.7 | 16.2 | 5.4 | 2.7 | 0.1875 |
| pN+ | 21 | 85.7 | 4.8 | 0.0 | 9.5 | — |
| Endometrioid carcinoma of the ovary | ||||||
| pT1 | 25 | 68.0 | 12.0 | 20.0 | 0.0 | 0.2860 |
| pT2 | 5 | 80.0 | 0.0 | 20.0 | 0.0 | — |
| pT3 | 6 | 100.0 | 0.0 | 0.0 | 0.0 | — |
| pN0 | 22 | 68.2 | 13.6 | 18.2 | 0.0 | 0.0609 |
| pN1 | 9 | 100.0 | 0.0 | 0.0 | 0.0 | — |
| Serous carcinoma of the ovary | ||||||
| pT1 | 33 | 81.8 | 6.1 | 9.1 | 3.0 | 0.0650 |
| pT2 | 45 | 71.1 | 8.9 | 17.8 | 2.2 | — |
| pT3 | 266 | 80.8 | 13.5 | 5.3 | 0.4 | — |
| pN0 | 84 | 77.4 | 10.7 | 10.7 | 1.2 | 0.8677 |
| pN1 | 169 | 78.7 | 12.4 | 7.7 | 1.2 | — |
| Squamous cell carcinomas of different sites* | ||||||
| pT1 | 225 | 87.1 | 10.7 | 1.8 | 0.4 | 0.5931 |
| pT2 | 226 | 85.8 | 12.8 | 0.9 | 0.4 | — |
| pT3 | 117 | 82.9 | 16.2 | 0.9 | 0.0 | — |
| pT4 | 109 | 89.0 | 10.1 | 0.0 | 0.9 | — |
| pN0 | 266 | 86.8 | 11.7 | 0.8 | 0.8 | 0.2684 |
| pN+ | 260 | 84.2 | 14.6 | 1.2 | 0.0 | — |
| G1 | 26 | 84.6 | 11.5 | 3.8 | 0.0 | 0.2907 |
| G2 | 370 | 87.8 | 11.1 | 0.3 | 0.8 | — |
| G3 | 234 | 83.3 | 14.5 | 1.7 | 0.4 | — |
*
Oral, pharynx, larynx, esophagues, cervix, vagina, vulva, penis, anal, skin, and lung.
ER indicates estrogen receptor; G, grade; pM, pathologic status of distant metastasis; pN, pathologic lymph node status; PR, progesterone receptor; pT, pathologic tumor stage.